For media enquiries, please contact email@example.com
Conyers Dill & Pearman advised Myovant Sciences Ltd. on a highly successful underwritten initial public offering on NYSE of 14,500,000 of its shares, for a total fundraising of US$218 million. Roivant Sciences Ltd., the parent company, remains the majority shareholder. This is the biggest New York IPO in the biotechnology sector so far in 2016 and is the latest biotechnology IPO to use a Bermuda company as the listing vehicle.
Neil Henderson, Robert Alexander and Edward Rance worked on the matter with Cooley LLP acting as US counsel to the issue and Latham & Watkins LLP acting as US counsel to the underwriters.